Nebenwirkungen · Firmagon
FIRMAGON 80 mg powder and solvent for solution for injection FIRMAGON 120 mg powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 5
HOS-120805 · Präparat HOS-095217
The most commonly observed adverse reactions during degarelix therapy in the confirmatory phase III study (N=409) were due to the expected physiological effects of testosterone suppression, including hot flushes and weight increase (reported in 25% and 7%, respectively, of patients receiving treatment for one year), or injection site adverse reactions. Transient chills, fever or influenza like illness were reported to occur hours after dosing (in 3%, 2% and 1% of patients, respectively).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-03-30T02:00:00Z · SHA-256 30eb95905f2a85834a14ebb60e9d230d12617fcceb70d78d157d98caee89b918 · Passage d828d7a911dd60e142a5c01943d57b7e9ea256c210161583e2e15649d3e15210 · Zeichen 31–523 im Abschnitt